UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma
brief summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of UCL70805F in patients with CD70-positive advanced renal clear cell carcinoma.
detailed description
This study will include two parts, dose escalation phase (modified "3+3" design) followed by a dose expansion phase.
All eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, followed by a single intravenous infusion of UCL70805F. The recommended phase 2 dose (RP2D) will be determined during the dose escalation phase. In the dose expansion phase, one or two dose levels may be selected to further characterize the safety profile and evaluate the efficacy of UCL70805F.
official title
An Exploratory Clinical Study to Evaluate the Safety and Preliminary Efficacy of UCL70805F in the Treatment of Patients With CD70-positive Advanced Renal Clear Cell Carcinoma